Terms: = Germ cell tumor AND PR, PGR, progesterone receptor AND Treatment
709 results:
1. Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.
Janssen JC; van Dijk B; de Joode K; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; van den Eertwegh AJM; de Groot JWB; Jalving M; de Jonge MJA; Joosse A; Kapiteijn E; Kamphuis-Huismans AM; Naipal KAT; Piersma D; Rikhof B; Westgeest HM; Vreugdenhil G; Oomen-de Hoop E; Mulder EEAP; van der Veldt AAM
BMC Cancer; 2024 May; 24(1):632. PubMed ID: 38783238
[TBL] [Abstract] [Full Text] [Related]
2. A nationwide phase II study of delayed local treatment for children with high-risk neuroblastoma: The Japan Children's Cancer Group Neuroblastoma Committee Trial JN-H-11.
Yoneda A; Shichino H; Hishiki T; Matsumoto K; Ohira M; Kamijo T; Kuroda T; Soejima T; Nakazawa A; Takimoto T; Yokota I; Teramukai S; Takahashi H; Fukushima T; Hara J; Kaneko M; Ikeda H; Tajiri T; Mugishima H; Nakagawara A
Pediatr Blood Cancer; 2024 Jun; 71(6):e30976. PubMed ID: 38577760
[TBL] [Abstract] [Full Text] [Related]
3. Role of immune checkpoint inhibitors combined with chemotherapy in recurrent drug-resistant gestational trophoblastic neoplasia: Four case reports and literature review.
Liu W; Zhu Y; Wang Y; Li R; Zou D; Chen R; Yang L; Huang Y
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2016. PubMed ID: 38425251
[TBL] [Abstract] [Full Text] [Related]
4. A retrospective study on the mechanism underlying quick transfer from response to resistance in a repeated recurrent chordoma patient with molecular alterations treated with Palbociclib.
Zhong N; Yu D; Yang M; Lu X; Zhang Q; Wei W; Jiao J; Yang X; Zhu Z; Chen S; Xiao J
J Cancer Res Clin Oncol; 2024 Feb; 150(2):95. PubMed ID: 38369555
[TBL] [Abstract] [Full Text] [Related]
5. Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial.
Sholler GLS; Bergendahl G; Lewis EC; Kraveka J; Ferguson W; Nagulapally AB; Dykema K; Brown VI; Isakoff MS; Junewick J; Mitchell D; Rawwas J; Roberts W; Eslin D; Oesterheld J; Wada RK; Pastakia D; Harrod V; Ginn K; Saab R; Bielamowicz K; Glover J; Chang E; Hanna GK; Enriquez D; Izatt T; Halperin RF; Moore A; Byron SA; Hendricks WPD; Trent JM
Genome Med; 2024 Feb; 16(1):28. PubMed ID: 38347552
[TBL] [Abstract] [Full Text] [Related]
6. The safety and efficacy of dabrafenib and trametinib in patients with glioma: A systematic review and meta-analysis.
Habibi MA; Mirjani MS; Ahmadvand MH; Delbari P; Alasti O
Eur J Clin Pharmacol; 2024 May; 80(5):639-656. PubMed ID: 38345637
[TBL] [Abstract] [Full Text] [Related]
7. Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma.
Lu Y; Liao L; Du K; Mo J; Zou X; Liang J; Chen J; Tang W; Su L; Wu J; Zhang J; Tan Y
BMC Cancer; 2024 Jan; 24(1):133. PubMed ID: 38273249
[TBL] [Abstract] [Full Text] [Related]
8. Targeted Therapy and Immunotherapy for Advanced Malignant Conjunctival tumors: Systematic Review.
Serbest Ceylanoglu K; Guneri Beser B; Singalavanija T; Juntipwong S; Worden FP; Demirci H
Ophthalmic Plast Reconstr Surg; 2024 Jan-Feb 01; 40(1):18-29. PubMed ID: 38241616
[TBL] [Abstract] [Full Text] [Related]
9. Combined Lanreotide Autogel and Temozolomide treatment of Progressive Pancreatic and Intestinal Neuroendocrine tumors: The Phase II SONNET Study.
Pavel M; Lahner H; Hörsch D; Rinke A; Denecke T; Koch A; Regnault B; Helbig D; Hoffmanns P; Raderer M
Oncologist; 2024 May; 29(5):e643-e654. PubMed ID: 38206830
[TBL] [Abstract] [Full Text] [Related]
10. Cobimetinib Plus Vemurafenib in Patients With Solid tumors With
Meric-Bernstam F; Rothe M; Mangat PK; Garrett-Mayer E; Gutierrez R; Ahn ER; Cannon TL; Powell S; Krauss JC; Reynolds CM; von Mehren M; Behl D; Calfa CJ; Duvivier HL; Kaplan HG; Livingston MB; Sharma MR; Urba WJ; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
JCO Precis Oncol; 2023 Sep; 7():e2300385. PubMed ID: 38096472
[TBL] [Abstract] [Full Text] [Related]
11. Radiogenomic landscape: Assessment of specific phagocytosis regulators in lower-grade gliomas.
Maimaiti A; Abulaiti A; Tang B; Dilixiati Y; Li X; Yakufu S; Wang Y; Jiang L; Shao H
Exp Biol Med (Maywood); 2023 Dec; 248(23):2289-2303. PubMed ID: 38062999
[TBL] [Abstract] [Full Text] [Related]
12. Nivolumab Plus Ipilimumab in Patients With Solid tumors With
Rohatgi N; Rothe M; Mangat PK; Garrett-Mayer E; Meric-Bernstam F; Pisick E; Alese OB; Reynolds CM; Thota R; Vaccaro GM; von Mehren M; Arend RC; Chiu VK; Duvivier HL; Gold PJ; Hack K; Marr AS; Winer A; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
JCO Precis Oncol; 2023 Sep; 7():e2300279. PubMed ID: 38039429
[TBL] [Abstract] [Full Text] [Related]
13. The features and management of acquired resistance to PD1-based therapy in metastatic melanoma.
Hepner A; Versluis JM; Wallace R; Allayous C; Brown LJ; Trojaniello C; Gerard CL; Jansen YJ; Bhave P; Neyns B; Haydon A; Michielin O; Mangana J; Klein O; Shoushtari AN; Warner AB; Ascierto PA; McQuade JL; Carlino MS; Zimmer L; Lebbe C; Johnson DB; Sandhu S; Atkinson V; Blank CU; Lo SN; Long GV; Menzies AM
Eur J Cancer; 2024 Jan; 196():113441. PubMed ID: 37988842
[TBL] [Abstract] [Full Text] [Related]
14. Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma.
Strowd R; Ellingson B; Raymond C; Yao J; Wen PY; Ahluwalia M; Piotrowski A; Desai A; Clarke JL; Lieberman FS; Desideri S; Nabors LB; Ye X; Grossman S
J Neurooncol; 2023 Oct; 165(1):101-112. PubMed ID: 37864646
[TBL] [Abstract] [Full Text] [Related]
15. Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours.
Maekawa N; Konnai S; Hosoya K; Kim S; Kinoshita R; Deguchi T; Owaki R; Tachibana Y; Yokokawa M; Takeuchi H; Kagawa Y; Takagi S; Ohta H; Kato Y; Yamamoto S; Yamamoto K; Suzuki Y; Okagawa T; Murata S; Ohashi K
PLoS One; 2023; 18(10):e0291727. PubMed ID: 37792729
[TBL] [Abstract] [Full Text] [Related]
16. receptor conversion and survival in breast cancer liver metastases.
Sundén M; Norgren S; Lundqvist R; Andersson A; Sund M; Hemmingsson O
Breast Cancer Res; 2023 Sep; 25(1):105. PubMed ID: 37705026
[TBL] [Abstract] [Full Text] [Related]
17. Pain and its interference with daily living in relation to cancer: a comparative population-based study of 16,053 cancer survivors and 106,345 people without cancer.
Joshy G; Khalatbari-Soltani S; Soga K; Butow P; Laidsaar-Powell R; Koczwara B; Rankin NM; Brown S; Weber M; Mazariego C; Grogan P; Stubbs J; Thottunkal S; Canfell K; Blyth FM; Banks E
BMC Cancer; 2023 Sep; 23(1):774. PubMed ID: 37700229
[TBL] [Abstract] [Full Text] [Related]
18. A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy.
Weiss SA; Sznol M; Shaheen M; Berciano-Guerrero MÁ; Couselo EM; Rodríguez-Abreu D; Boni V; Schuchter LM; Gonzalez-Cao M; Arance A; Wei W; Ganti AK; Hauke RJ; Berrocal A; Iannotti NO; Hsu FJ; Kluger HM
Clin Cancer Res; 2024 Jan; 30(1):74-81. PubMed ID: 37535056
[TBL] [Abstract] [Full Text] [Related]
19. Lung cancer with breast metastasis: a case report and review of the literature.
Cao X; Chen P; Agyekum EA; Zhang Q; Qian X; Wu T; Chambers KH; Yin L
J Int Med Res; 2023 Jul; 51(7):3000605231188287. PubMed ID: 37523488
[TBL] [Abstract] [Full Text] [Related]
20. Phase II study of border zone stereotactic radiosurgery with bevacizumab in patients with recurrent or progressive glioblastoma multiforme.
Mantica M; Drappatz J; Lieberman F; Hadjipanayis CG; Lunsford LD; Niranjan A
J Neurooncol; 2023 Aug; 164(1):179-190. PubMed ID: 37515669
[TBL] [Abstract] [Full Text] [Related]
[Next]
